Innovation Pharmaceuticals Inc (IPIX)

[runninggirl2016]

From 10/26 PR

Regarding the planned Phase 2a study of Kevetrin, a p53-activating anti-cancer agent, in late-stage ovarian cancer, the protocol is undergoing a final internal review before submission to the FDA, a process expected to be completed next month.


If they made the November date I think we would have been told. AT least I hope we would have.

Looks like Prurisol is the only candidate that's gonna drive the SP up in the coming months.

GO PRURISGOLD!!!